Biogen Idec Deeply Undervalued – Analyst Blog
Source: http://www.zacks.com/stock/news/16412/Biogen+Idec+Deeply+Undervalued+-+Analyst+BlogPosted on Tuesday, December 16th, 2008 | In Stocks to Watch
Biogen Idec Inc. (BIIB) posted solid results in the third quarter of 2008, despite the slowdown in Tysabri sales due to fears of PML. We think the Biogen core business will remain strong over the next several quarters, and that Tysabri prescriptions will resume their previous pace shortly.
In the meantime, the name is significantly undervalued and would be a very attractive takeout candidate for a large-cap pharmaceutical company looking for a great phase-III pipeline. We expect 2009 to be an eventful year on the pipeline front.
As investors become more comfortable with both Tysabri trends and Biogen’s emerging pipeline, we believe shares will recover back into the high $50’s. At today’s price, the name is too attractive to ignore.
Read the full analyst report on BIIB.
“BIIB” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
Biogen Idec Inc., Blog, large-cap pharmaceutical company looking;, Stocks to Watch, Tysabri, USD, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.